Targeted therapies in thyroid cancer

被引:4
作者
Capdevila, Jaume [1 ]
Perez-Garcia, Jose [1 ]
Obiols, Gabriel [2 ]
Tabernero, Josep [1 ]
机构
[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona 08035, Spain
[2] Vall dHebron Univ Hosp, Dept Endocrinol, Barcelona 08035, Spain
关键词
Differentiated thyroid cancer; Medullary thyroid cancer; Targeted therapy; Sorafenib; Motesanib; Axitinib; Vandetanib; Sunitinib; Thalidomide; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; DOXORUBICIN PLUS CISPLATIN; TUMOR ANGIOGENESIS; SIGNALING PATHWAY; BRAF MUTATIONS; SOLID TUMORS; CELL-GROWTH; PAPILLARY; CARCINOMA;
D O I
10.1007/s11523-009-0124-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Differentiated thyroid carcinoma is the most frequent neoplasm of the endocrine system. Although thyroid cancer usually has an excellent prognosis, no therapeutic options are available for patients that develop metastases and are or became resistant to radioiodine therapy. The deeper knowledge of molecular aberrations that characterize tumor growth has provided novel targets in cancer therapy. Several proteins have been implicated as having a crucial role in the carcinogenesis of differentiated thyroid cancer, such as those involved in RET/PTC-RAS-RAF-MAPK pathway. Moreover, vascular aberrations and angiogenesis equilibrium have also been related to tumor growth. The development of new, targeted therapies and their encouraging initial results have opened a hopeful opportunity of treatment for these orphan therapy tumor patients.
引用
收藏
页码:275 / 285
页数:11
相关论文
共 69 条
[1]  
AGARWAL R, 2008, P AN M AM SOC CLIN, V26, P3535
[2]  
AIN KB, 2008, P AN M AM SOC CLIN, V26, P6027
[3]   Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas [J].
Ain, Kenneth B. ;
Lee, Charles ;
Williams, Kevin D. .
THYROID, 2007, 17 (07) :663-670
[4]   Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice [J].
Bauer, AJ ;
Terrell, R ;
Doniparthi, NK ;
Patel, A ;
Tuttle, RM ;
Saji, M ;
Ringel, MD ;
Francis, GL .
THYROID, 2002, 12 (11) :953-961
[5]  
BRITTEN CD, 2001, CANCER CHEMOTH PHARM, V61, P515
[6]   BAY 43-9006 inhibition of oncogenic RET mutants [J].
Carlomagno, F ;
Anaganti, S ;
Guida, T ;
Salvatore, G ;
Troncone, G ;
Wilhelm, SM ;
Santoro, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05) :326-334
[7]  
Casamassimi A, 1998, CANCER RES, V58, P2888
[8]  
Chan JKC., 2004, World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Endocrine Organs, P98
[9]  
CHEN J, 2002, MOL CELL BIOL, V13, P4107
[10]   Sunitinib: From rational design to clinical efficacy [J].
Chow, Laura Q. M. ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :884-896